Director Nilda Mesa filed a Form 4 with the SEC on September 15, 2026, reporting the exercise of a stock option and subsequent sale of common stock in United Therapeutics Corp (NASDAQ:UTHR) on September 14, 2026.

Key Highlights

  • Option exercise: Mesa acquired 130 shares of common stock via stock option exercise (transaction code M) at a price of $110.86 per share on September 14, 2026.
  • First sale: 130 shares were sold at a weighted average price of $505.7868 per share, with individual trade prices ranging from $505.76 to $505.985.
  • Second sale: An additional 98 shares were sold at $505.975 per share on the same date.
  • Resulting ownership: Following all reported transactions, Mesa directly held 5,580 shares of common stock.
  • Derivative securities: 6,430 stock options with a $110.86 exercise price and an expiration date of October 31, 2028, remained beneficially owned directly after the transactions.
  • Filing role: Mesa is identified in the filing as a Director of United Therapeutics Corp.

Mesa Option Exercise and Share Sales at United Therapeutics

According to the filing, Director Nilda Mesa executed three transactions in United Therapeutics common stock on September 14, 2026. The first was an option exercise (transaction code M) of 130 shares at the option's exercise price of $110.86 per share, bringing her directly held common stock to 6,560 shares at that point. The stock option exercised had an original exercise date of October 31, 2019, and carries an expiration date of October 31, 2028, per the filing's Table II.

Following the exercise, the filing reports two separate sale transactions on the same date. Mesa sold 130 shares at a weighted average price of $505.7868 per share. The filing discloses that this transaction was executed in multiple trades at prices ranging from $505.76 to $505.985, and that Mesa "undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected." A second sale of 98 shares was then reported at $505.975 per share.

After all three transactions, Mesa's direct beneficial ownership of common stock stood at 5,580 shares, according to the filing. Separately, 6,430 stock options with a $110.86 exercise price are listed in Table II as directly owned following the reported transactions. The Form 4 was signed by John S. Hess, Jr. under Power of Attorney and filed on September 15, 2026.

What Was Disclosed

The filing reported a stock option exercise of 130 shares at $110.86 and two subsequent open-market sales totaling 228 shares by United Therapeutics Director Nilda Mesa on September 14, 2026, leaving her with 5,580 directly held common shares.